Allogeneic transplantation in primary refractory AML

被引：4
作者：
Ferguson, P. [1 ]
Craddock, C. [1 ,2 ]
机构：
[1] Queen Elizabeth Hosp, Ctr Clin Haematol, Birmingham B15 2TH, W Midlands, England
[2] Univ Birmingham, Inst Canc & Genom Sci, Canc Res UK Clin Trials Unit CRCTU, Birmingham, W Midlands, England
来源：
BONE MARROW TRANSPLANTATION | 2017年 / 52卷 / 07期
关键词：
ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; INTERNATIONAL EXPERT PANEL; PRIMARY INDUCTION FAILURE; RECOMMENDATIONS; DIAGNOSIS; RELAPSE; MANAGEMENT; OUTCOMES;
D O I：
10.1038/bmt.2017.61
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：950 / 951
页数：2
相关论文
共 50 条
  • [41] Allogeneic stem cell transplantation for non-de novo AML or advanced myelodysplastic syndromes: influence of GvHD and donor lymphocyte infusions on long-term outcome
    Hemmati, P. G.
    Pfeifer, K.
    Vuong, L. G.
    Jehn, C. F.
    Terwey, T. H.
    le Coutre, P.
    Doerken, B.
    Arnold, R.
    BONE MARROW TRANSPLANTATION, 2018, 53 (01) : 101 - 103
  • [42] Autologous and Allogeneic Stem Cell Transplantation as Salvage Treatment Options for Relapsed/Refractory Multiple Myeloma: A Single-center Experience over 20 Years
    Steiner, Normann
    Schober, Paula
    Willenbacher, Wolfgang
    Kircher, Brigitte
    Gunsilius, Eberhard
    Wolf, Dominik
    Nachbaur, David
    ANTICANCER RESEARCH, 2022, 42 (12) : 5825 - 5832
  • [43] Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial
    Middeke, J. M.
    Herbst, R.
    Parmentier, S.
    Bug, G.
    Haenel, M.
    Stuhlers, G.
    Schaefer-Eckart, K.
    Roester, W.
    Klein, S.
    Bethge, W.
    Bitz, U.
    Buettner, B.
    Knoth, H.
    Alakel, N.
    Schaich, M.
    Morgner, A.
    Kramer, M.
    Sockel, K.
    von Bonin, M.
    Stoelzel, F.
    Platzbecker, U.
    Roellig, C.
    Thiede, C.
    Ehninger, G.
    Bornhaeuser, M.
    Schetelig, J.
    LEUKEMIA, 2016, 30 (02) : 261 - 267
  • [44] Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?
    K W Song
    J Lipton
    Bone Marrow Transplantation, 2005, 36 : 183 - 191
  • [45] Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?
    Song, KW
    Lipton, J
    BONE MARROW TRANSPLANTATION, 2005, 36 (03) : 183 - 191
  • [46] Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy
    Kattner, Anna-Sophia
    Holler, Ernst
    Herr, Wolfgang
    Reichle, Albrecht
    Wolff, Daniel
    Heudobler, Daniel
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [47] Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
    Kunadt, Desiree
    Stasik, Sebastian
    Metzeler, Klaus H.
    Roellig, Christoph
    Schliemann, Christoph
    Greif, Philipp A.
    Spiekermann, Karsten
    Rothenberg-Thurley, Maja
    Krug, Utz
    Braess, Jan
    Kraemer, Alwin
    Hochhaus, Andreas
    Scholl, Sebastian
    Hilgendorf, Inken
    Bruemmendorf, Tim H.
    Jost, Edgar
    Steffen, Bjoern
    Bug, Gesine
    Einsele, Hermann
    Goerlich, Dennis
    Sauerland, Cristina
    Schaefer-Eckart, Kerstin
    Krause, Stefan W.
    Haenel, Mathias
    Hanoun, Maher
    Kaufmann, Martin
    Woermann, Bernhard
    Kramer, Michael
    Sockel, Katja
    Egger-Heidrich, Katharina
    Herold, Tobias
    Ehninger, Gerhard
    Burchert, Andreas
    Platzbecker, Uwe
    Berdel, Wolfgang E.
    Mueller-Tidow, Carsten
    Hiddemann, Wolfgang
    Serve, Hubert
    Stelljes, Matthias
    Baldus, Claudia D.
    Neubauer, Andreas
    Schetelig, Johannes
    Thiede, Christian
    Bornhaeuser, Martin
    Middeke, Jan M.
    Stoelzel, Friedrich
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [48] Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR
    Novitzky-Basso, Igor
    Chen, Carol
    Chen, Shiyi
    Lipton, Jeffrey H.
    Kim, Dennis D.
    Viswabandya, Auro
    Kumar, Rajat
    Lam, Wilson
    Law, Arjun
    Al-Shaibani, Zeyad
    Gerbitz, Armin
    Pasic, Ivan
    Mattsson, Jonas
    Michelis, Fotios V.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (03) : 354 - 363
  • [49] Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML
    Christopoulos, P.
    Schmoor, C.
    Waterhouse, M.
    Marks, R.
    Waesch, R.
    Bertz, H.
    Finke, J.
    BONE MARROW TRANSPLANTATION, 2013, 48 (07) : 901 - 907
  • [50] Allogeneic transplantation as anticancer immunotherapy
    Parmar, Simrit
    Ritchie, David S.
    CURRENT OPINION IN IMMUNOLOGY, 2014, 27 : 38 - 45
12345